Jiangsu Bioperfectus Technologies Co., Ltd. Stock

Equities

688399

CNE1000055B2

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
73.44 CNY -0.30% Intraday chart for Jiangsu Bioperfectus Technologies Co., Ltd. +10.37% +34.60%

Financials

Sales 2022 5.53B 765M 1.05B Sales 2023 403M 55.69M 76.47M Capitalization 3.2B 442M 607M
Net income 2022 1.83B 252M 347M Net income 2023 -374M -51.66M -70.93M EV / Sales 2022 0.44 x
Net cash position 2022 2.7B 373M 513M Net cash position 2023 2.29B 316M 434M EV / Sales 2023 2.25 x
P/E ratio 2022
2.81 x
P/E ratio 2023
-8.55 x
Employees 1,082
Yield 2022 *
-
Yield 2023
-
Free-Float 55.65%
More Fundamentals * Assessed data
Dynamic Chart
Jiangsu Bioperfectus Technologies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Bioperfectus Technologies Gets Nod to Register Hepatitis B Detection Kit MT
Jiangsu Bioperfectus Technologies Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jiangsu Bioperfectus Technologies Co., Ltd.(XSSC:688399) dropped from S&P Global BMI Index CI
Jiangsu Bioperfectus Technologies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Bioperfectus Elects Chairman, General Manager MT
Jiangsu Bioperfectus Technologies Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jiangsu Bioperfectus Technologies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Jiangsu Bioperfectus Technologies Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Jiangsu Bioperfectus Technologies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Jiangsu Bioperfectus Technologies Co., Ltd.(XSSC:688399) added to S&P Global BMI Index CI
Jiangsu Bioperfectus Technologies Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Test makers target monkeypox market as cases surge RE
Jiangsu Bioperfectus Technologies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Jiangsu Bioperfectus Technologies Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day-0.30%
1 week+10.37%
Current month+7.92%
1 month+7.92%
3 months+30.63%
6 months+42.19%
Current year+34.60%
More quotes
1 week
66.01
Extreme 66.01
74.79
1 month
65.00
Extreme 65
74.79
Current year
49.02
Extreme 49.02
74.79
1 year
46.52
Extreme 46.52
74.79
3 years
46.52
Extreme 46.52
219.60
5 years
46.52
Extreme 46.52
476.76
10 years
46.52
Extreme 46.52
476.76
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 10-03-31
Director of Finance/CFO 40 23-06-29
Chief Tech/Sci/R&D Officer 55 10-07-31
Members of the board TitleAgeSince
Director/Board Member 56 17-07-31
Director/Board Member 70 11-02-28
Chief Executive Officer 54 10-03-31
More insiders
Date Price Change Volume
24-04-30 73.44 -0.30% 519,175
24-04-29 73.66 +7.61% 1,158,298
24-04-26 68.45 +1.56% 598,696
24-04-25 67.4 +1.26% 541,106
24-04-24 66.56 +0.02% 158,730

End-of-day quote Shanghai S.E., April 29, 2024

More quotes
Jiangsu Bioperfectus Technologies Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic products. The Company's products mainly include in vitro diagnostic reagents, supporting testing instruments and in vitro testing services. Its products are mainly used in the fields of infectious disease prevention and control, clinical testing, large-scale population screening, as well as prenatal and postnatal care management. The Company mainly conducts its businesses in domestic and overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. 688399 Stock